Wednesday, April 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

UN health agency sets higher, tougher bar for air quality

The harmful health effects of air pollution kick in at lower levels than previously thought, the World Health Organization said as it set a new standard for policymakers and the public in the first update of its air quality guidelines in 15 years.

The U.N. health agency released its revised guidance as climate change is a leading topic at the U.N. General Assembly in New York. Chinese President Xi Jinping announced Tuesday that China will no longer fund power plants fired by coal, which generates several of the pollutants covered by the guidelines.

Since the last update of the WHO recommendations, better monitoring and science have cleared up the global picture about the effects of six major air pollutants on human health. According to the agency, 90% of the world’s people already live in areas with at least one particularly harmful type of pollutant.

Source: AP News

https://apnews.com/article/united-nations-general-assembly-health-climate-environment-and-nature-xi-jinping-e0684e616ceef22462b8bb5db1c2d1eb

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!